JP6450679B2 - マルチマーカーリスク層別化 - Google Patents
マルチマーカーリスク層別化 Download PDFInfo
- Publication number
- JP6450679B2 JP6450679B2 JP2015528625A JP2015528625A JP6450679B2 JP 6450679 B2 JP6450679 B2 JP 6450679B2 JP 2015528625 A JP2015528625 A JP 2015528625A JP 2015528625 A JP2015528625 A JP 2015528625A JP 6450679 B2 JP6450679 B2 JP 6450679B2
- Authority
- JP
- Japan
- Prior art keywords
- subject
- age
- risk score
- risk
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003550 marker Substances 0.000 title claims description 41
- 238000013517 stratification Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 132
- 230000001965 increasing effect Effects 0.000 claims description 29
- 231100000225 lethality Toxicity 0.000 claims description 28
- 206010019280 Heart failures Diseases 0.000 claims description 27
- 238000004422 calculation algorithm Methods 0.000 claims description 27
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 25
- 231100000518 lethal Toxicity 0.000 claims description 25
- 230000001665 lethal effect Effects 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 8
- 230000035488 systolic blood pressure Effects 0.000 claims description 7
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 5
- 101710158332 Diuretic hormone Proteins 0.000 claims 1
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 83
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 description 81
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 description 78
- 238000011282 treatment Methods 0.000 description 44
- 230000015654 memory Effects 0.000 description 35
- 102000004903 Troponin Human genes 0.000 description 32
- 108090001027 Troponin Proteins 0.000 description 32
- 238000011156 evaluation Methods 0.000 description 30
- 238000012544 monitoring process Methods 0.000 description 19
- 230000000747 cardiac effect Effects 0.000 description 16
- 238000004891 communication Methods 0.000 description 16
- 208000029078 coronary artery disease Diseases 0.000 description 15
- 238000013459 approach Methods 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000000750 progressive effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 8
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 7
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010007556 Cardiac failure acute Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 102400001263 NT-proBNP Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 5
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 238000011256 aggressive treatment Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- -1 NTpro-BNP Proteins 0.000 description 2
- 108020001621 Natriuretic Peptide Proteins 0.000 description 2
- 102000004571 Natriuretic peptide Human genes 0.000 description 2
- 101150095505 ST2 gene Proteins 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 102000055002 human IL1RL1 Human genes 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000692 natriuretic peptide Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100025477 GTP-binding protein Rit1 Human genes 0.000 description 1
- 102100027778 GTP-binding protein Rit2 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101001111714 Homo sapiens RING-box protein 2 Proteins 0.000 description 1
- 101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000013131 cardiovascular procedure Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Health & Medical Sciences (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691706P | 2012-08-21 | 2012-08-21 | |
| US61/691,706 | 2012-08-21 | ||
| PCT/US2013/056020 WO2014031764A1 (en) | 2012-08-21 | 2013-08-21 | Multimarker risk stratification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018230514A Division JP6621520B2 (ja) | 2012-08-21 | 2018-12-10 | マルチマーカーリスク層別化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015532715A JP2015532715A (ja) | 2015-11-12 |
| JP6450679B2 true JP6450679B2 (ja) | 2019-01-09 |
Family
ID=50148799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528625A Expired - Fee Related JP6450679B2 (ja) | 2012-08-21 | 2013-08-21 | マルチマーカーリスク層別化 |
| JP2018230514A Expired - Fee Related JP6621520B2 (ja) | 2012-08-21 | 2018-12-10 | マルチマーカーリスク層別化 |
| JP2019208375A Expired - Fee Related JP6902083B2 (ja) | 2012-08-21 | 2019-11-19 | マルチマーカーリスク層別化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018230514A Expired - Fee Related JP6621520B2 (ja) | 2012-08-21 | 2018-12-10 | マルチマーカーリスク層別化 |
| JP2019208375A Expired - Fee Related JP6902083B2 (ja) | 2012-08-21 | 2019-11-19 | マルチマーカーリスク層別化 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20140058743A1 (enExample) |
| EP (1) | EP2888687B1 (enExample) |
| JP (3) | JP6450679B2 (enExample) |
| CN (2) | CN104737170A (enExample) |
| AU (3) | AU2013305829A1 (enExample) |
| CA (1) | CA2882303A1 (enExample) |
| HK (2) | HK1208092A1 (enExample) |
| IN (1) | IN2015DN01767A (enExample) |
| MX (2) | MX375520B (enExample) |
| RU (1) | RU2015110054A (enExample) |
| SG (2) | SG10201608854TA (enExample) |
| WO (1) | WO2014031764A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| ES2375181T3 (es) | 2002-05-09 | 2012-02-27 | The Brigham And Women's Hospital, Inc. | 1l 1rl-1 como un marcador de enfermedades cardiovasculares. |
| PL2386860T4 (pl) | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Przewidywanie śmiertelności i wykrywanie poważnej choroby |
| DK2482078T3 (en) | 2006-05-01 | 2016-05-02 | Critical Care Diagnostics Inc | Cardiovascular disease diagnosis |
| PT3093663T (pt) | 2008-04-18 | 2018-10-19 | Critical Care Diagnostics Inc | Previsão do risco de eventos cardíacos adversos maiores |
| RU2684724C2 (ru) | 2010-04-09 | 2019-04-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| PL2734222T3 (pl) | 2011-07-18 | 2017-03-31 | Critical Care Diagnostics, Inc. | Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej |
| AU2013262515B2 (en) | 2012-05-18 | 2018-03-15 | Cardiac Pacemakers, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX358541B (es) | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
| IN2015DN01767A (enExample) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| US20150199491A1 (en) * | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| CA2996903C (en) | 2015-08-28 | 2024-01-02 | Mcmaster University | Method of determining risk of an adverse cardiac event |
| US20170220749A1 (en) * | 2016-02-01 | 2017-08-03 | MD Aware LLC | Systems and methods for identifying and using medical calculators |
| EP3446124B1 (en) * | 2016-04-18 | 2026-08-05 | Roche Diagnostics GmbH | Soluble st2 for the identification of progressors to lvh in the general population |
| US12014832B2 (en) * | 2017-06-02 | 2024-06-18 | University Of Florida Research Foundation, Incorporated | Method and apparatus for prediction of complications after surgery |
| RU2677611C1 (ru) * | 2018-04-16 | 2019-01-17 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| EP3969620B1 (en) * | 2019-05-17 | 2025-06-25 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| US20220399122A1 (en) * | 2019-11-01 | 2022-12-15 | Nec Corporation | Risk prediction apparatus, risk prediction method, and computer program |
| CN118760892B (zh) * | 2024-09-05 | 2024-11-19 | 温州市中心医院 | 铁死亡评分确定方法、系统及设备 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
| JPH0731479Y2 (ja) | 1989-06-02 | 1995-07-19 | 内橋エステック株式会社 | 温度ヒューズ |
| US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
| JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体 |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| JP2732005B2 (ja) | 1992-12-14 | 1998-03-25 | 眞一 富永 | ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法 |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| AU7235296A (en) | 1996-08-23 | 1998-03-06 | Human Genome Sciences, Inc. | T1 receptor-like ligand ii |
| CA2282401A1 (en) | 1997-02-28 | 1998-09-03 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
| WO1998043630A1 (en) | 1997-04-02 | 1998-10-08 | Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
| US6210976B1 (en) | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| AU731858B2 (en) | 1997-09-11 | 2001-04-05 | Shionogi & Co., Ltd. | Immunoassay for BNP |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
| AU2055300A (en) | 1998-12-18 | 2000-07-03 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
| AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| FR2795823B1 (fr) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| FR2807170B1 (fr) | 2000-03-30 | 2002-06-28 | Sipal | Charniere elastique a frottement reduit |
| RU2002110275A (ru) | 2000-08-22 | 2004-03-27 | Дзе Брихэм Энд Уимен'З Хоспитал, Инк. (Us) | Диагностика и лечение сердечно-сосудистых состояний |
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
| FI20010019A7 (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen gastriitin diagnostisoimiseksi |
| US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| EP1322957B1 (en) | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
| US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
| ES2375181T3 (es) | 2002-05-09 | 2012-02-27 | The Brigham And Women's Hospital, Inc. | 1l 1rl-1 como un marcador de enfermedades cardiovasculares. |
| US8263325B2 (en) | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
| AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
| US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
| US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| US20050123451A1 (en) | 2003-10-31 | 2005-06-09 | Hiroshi Nomura | System and apparatus for body fluid analysis using surface-textured optical materials |
| EP1711622A2 (en) | 2003-11-26 | 2006-10-18 | Applera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| AU2004296829A1 (en) | 2003-12-05 | 2005-06-23 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
| US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| CA2595794A1 (en) | 2005-01-24 | 2006-07-27 | F. Hoffmann-La Roche Ag | The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
| EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| US20070021977A1 (en) | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
| JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
| PL2386860T4 (pl) | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Przewidywanie śmiertelności i wykrywanie poważnej choroby |
| ATE517341T1 (de) | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen |
| DK2482078T3 (en) | 2006-05-01 | 2016-05-02 | Critical Care Diagnostics Inc | Cardiovascular disease diagnosis |
| SI2019965T1 (sl) | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics, Inc. | Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja |
| WO2007130627A2 (en) | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
| RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
| CA2554659A1 (en) * | 2006-07-25 | 2006-11-24 | 1128971 Alberta Ltd. | Hanger flange for hanging a tubular body in a well |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| JP2010526555A (ja) * | 2007-05-11 | 2010-08-05 | タフツ・メディカル・センター | 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法 |
| WO2009040133A1 (en) * | 2007-09-26 | 2009-04-02 | Universitätsklinikum Heidelberg | Osteopontin as novel prognostic biomarker for heart failure |
| FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
| WO2009075566A1 (en) * | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| PT3093663T (pt) | 2008-04-18 | 2018-10-19 | Critical Care Diagnostics Inc | Previsão do risco de eventos cardíacos adversos maiores |
| US20100159474A1 (en) * | 2008-11-11 | 2010-06-24 | B.R.A.H.M.S. Aktiengesellschaft | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
| CA2765516A1 (en) * | 2009-07-01 | 2011-01-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting cardiovascular mortality risk |
| EP2568294B1 (en) * | 2009-11-13 | 2015-01-07 | BG Medicine, Inc. | Risk Factors and Prediction of Myocardial Infaraction |
| US8258456B2 (en) * | 2009-11-27 | 2012-09-04 | Himax Imaging, Inc. | Image sensor |
| RU2684724C2 (ru) | 2010-04-09 | 2019-04-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
| RU2017110678A (ru) * | 2010-11-01 | 2019-01-24 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
| RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| PL2734222T3 (pl) | 2011-07-18 | 2017-03-31 | Critical Care Diagnostics, Inc. | Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej |
| AU2013262515B2 (en) | 2012-05-18 | 2018-03-15 | Cardiac Pacemakers, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX358541B (es) | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
| IN2015DN01767A (enExample) | 2012-08-21 | 2015-05-29 | Critical Care Diagnostics Inc | |
| JP6178687B2 (ja) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | グラビア塗工装置 |
| US20150199491A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
| USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2013
- 2013-08-21 IN IN1767DEN2015 patent/IN2015DN01767A/en unknown
- 2013-08-21 MX MX2015002254A patent/MX375520B/es active IP Right Grant
- 2013-08-21 CN CN201380054795.8A patent/CN104737170A/zh active Pending
- 2013-08-21 JP JP2015528625A patent/JP6450679B2/ja not_active Expired - Fee Related
- 2013-08-21 CN CN202010424423.1A patent/CN111834009A/zh active Pending
- 2013-08-21 US US13/972,596 patent/US20140058743A1/en not_active Abandoned
- 2013-08-21 AU AU2013305829A patent/AU2013305829A1/en not_active Abandoned
- 2013-08-21 EP EP13831501.5A patent/EP2888687B1/en active Active
- 2013-08-21 SG SG10201608854TA patent/SG10201608854TA/en unknown
- 2013-08-21 RU RU2015110054A patent/RU2015110054A/ru not_active Application Discontinuation
- 2013-08-21 WO PCT/US2013/056020 patent/WO2014031764A1/en not_active Ceased
- 2013-08-21 HK HK15108723.0A patent/HK1208092A1/xx unknown
- 2013-08-21 HK HK15112621.5A patent/HK1212057A1/xx unknown
- 2013-08-21 SG SG11201501271TA patent/SG11201501271TA/en unknown
- 2013-08-21 CA CA2882303A patent/CA2882303A1/en not_active Abandoned
-
2015
- 2015-02-20 MX MX2020009943A patent/MX2020009943A/es unknown
-
2016
- 2016-12-20 US US15/385,095 patent/US10303844B2/en active Active
-
2018
- 2018-12-10 JP JP2018230514A patent/JP6621520B2/ja not_active Expired - Fee Related
-
2019
- 2019-03-13 AU AU2019201709A patent/AU2019201709B2/en not_active Ceased
- 2019-04-10 US US16/380,513 patent/US10741290B2/en not_active Expired - Fee Related
- 2019-11-19 JP JP2019208375A patent/JP6902083B2/ja not_active Expired - Fee Related
-
2020
- 2020-07-07 US US16/922,580 patent/US20200335220A1/en not_active Abandoned
-
2021
- 2021-04-06 AU AU2021202116A patent/AU2021202116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6621520B2 (ja) | 2019-12-18 |
| JP2020034573A (ja) | 2020-03-05 |
| US20200335220A1 (en) | 2020-10-22 |
| JP2015532715A (ja) | 2015-11-12 |
| MX2015002254A (es) | 2015-05-08 |
| JP2019053086A (ja) | 2019-04-04 |
| US10303844B2 (en) | 2019-05-28 |
| CN111834009A (zh) | 2020-10-27 |
| AU2013305829A1 (en) | 2015-03-05 |
| EP2888687A4 (en) | 2016-04-13 |
| US20190237197A1 (en) | 2019-08-01 |
| SG10201608854TA (en) | 2016-12-29 |
| HK1212057A1 (en) | 2016-06-03 |
| EP2888687B1 (en) | 2023-08-02 |
| IN2015DN01767A (enExample) | 2015-05-29 |
| MX375520B (es) | 2025-03-06 |
| CA2882303A1 (en) | 2014-02-27 |
| US20170169179A1 (en) | 2017-06-15 |
| AU2021202116A1 (en) | 2021-05-06 |
| JP6902083B2 (ja) | 2021-07-14 |
| RU2015110054A (ru) | 2016-10-10 |
| AU2019201709A1 (en) | 2019-04-04 |
| AU2019201709B2 (en) | 2021-01-07 |
| US10741290B2 (en) | 2020-08-11 |
| MX2020009943A (es) | 2020-10-16 |
| CN104737170A (zh) | 2015-06-24 |
| WO2014031764A1 (en) | 2014-02-27 |
| EP2888687A1 (en) | 2015-07-01 |
| HK1208092A1 (en) | 2016-02-19 |
| SG11201501271TA (en) | 2015-03-30 |
| US20140058743A1 (en) | 2014-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6621520B2 (ja) | マルチマーカーリスク層別化 | |
| Núñez et al. | Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis | |
| Patel et al. | A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease | |
| JP6788050B2 (ja) | 主要有害心イベントのリスクを予測する方法 | |
| US11404166B2 (en) | Systems and methods for mining of medical data | |
| Oudejans et al. | Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests | |
| Frank Peacock et al. | Short‐term mortality risk in emergency department acute heart failure | |
| Krim et al. | Racial/ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines–Heart Failure | |
| Weekes et al. | Intermediate-risk pulmonary embolism: echocardiography predictors of clinical deterioration | |
| Kanagala et al. | Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction | |
| Huang et al. | Development and validation of a nomogram to predict the risk of death within 1 year in patients with non-ischemic dilated cardiomyopathy: a retrospective cohort study | |
| Durrington et al. | NT‐proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring | |
| Mavrea et al. | Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania | |
| Shen et al. | Cohort research in “Omics” and preventive medicine | |
| Güvenç et al. | Estimated plasma volume is not a robust indicator of the severity of congestion in patients with heart failure | |
| Zhang et al. | Machine learning-based mortality prediction of 90-day discharge in acute coronary syndrome patients | |
| Zamudio et al. | From pruritus to cholestasis: Building a statistical model and online application to predict a diagnosis prior to bile acid determination | |
| Nagai et al. | Right ventricular free wall longitudinal strain assessment using offline speckle tracking in COVID-19 patients requiring intensive medical care | |
| Meng et al. | Association of Free Triiodothyronine with Long-Term Prognosis in Hypertrophic cardiomyopathy patients with HFpEF: A Dual center research study | |
| Kociol et al. | Admission, discharge, or change in BNP and long-term outcomes: data from OPTIMIZE-HF linked to medicare claims | |
| Lu et al. | Correlation between the frailty index derived from laboratory tests and 4-week all-cause mortality in critically ill patients with pneumonia | |
| Kurtinecz | B-type and N-terminal Pro-B-type Natriuretic Peptides in Heart Failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160606 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6450679 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |